Ampersand Capital Partners is pleased to announce the closing of the firm’s latest fund, Ampersand 2022 (“AMP-22”) Limited Partnership, with $1.2 billion in limited partner commitments. This fund, which is Ampersand’s eleventh primary fund since 1992, was significantly oversubscribed and held a single close less than three months after launch. Ampersand secured commitments from a diversified and global set of institutional investors including endowments, foundations, pension plans, insurance companies, funds of funds, and family offices.

For more than 30 years, Ampersand has been a trusted partner to founders and CEOs, helping to accelerate growth and build numerous market-leading companies across the firm’s core healthcare sectors. With this new fund, Ampersand intends to continue the firm’s strategy of partnering with great entrepreneurs within our core sectors through both majority and minority investments in companies with $10 to $100 million in revenue and positive EBITDA.  

Goodwin Procter LLP provided legal services to Ampersand for this fundraise.

Read more: PR Newswire